CD Genomics Launches NGS Panels for SARS-CoV-2 Detection and Research

May 28, 2020

SHIRLEY, NY, UNITED STATES - May 20, 2020 - CD Genomics has developed a very comprehensive NGS panels for sequencing, coronaviruses detection, phylogenetic analysis and molecular characterization of the 2019 novel coronavirus (namely SARS-CoV-2, and the virus is responsible for COVID-19). The panels are designed to obtain complete viral genomes and molecular mechanisms from samples even with very low SARS-CoV-2 viral content.

The NGS Panels mainly includes three categories: CDAMP® SARS-CoV-2 Panel Kit,    CDCAP® β-CoVs Panel Kit and CDCAP® Respiratory Virus Panel Kit.

The CDAMP® SARS-CoV-2 Panel Kit is a highly multiplexed target enrichment panel that covers the entire genome of SARS-CoV-2 virus. In less than 6 hours, the purified RNA sample can be amplified to libraries by CD Genomics’ fast and simple workflow. Moreover, the panel is mutation tolerant to allow sequence variability. Panels generate highly accurate data from minimal RNA input. It is designed for detection, identification, and mutation analysis of SARS-CoV-2 and other coronaviruses.

CDCAP® β-CoVs Panel Kit and CDCAP® Respiratory Virus Panel Kit is based on Illumina platforms. It is specially designed for target enrichment and library preparation using a fast and simple workflow. The former is a hybridization capture-based target enrichment panel covering the entire genome of SARS-CoV-2 virus and other betacoronavirus. It is designed for detection, identification, and mutation analysis of SARS-CoV-2 and other betacoronavirus. The latter is a hybridization capture-based target enrichment panel covering 36 respiratory disease-related viruses, such as SARS-CoV-1, MERS-CoV, SARS-CoV-2, influenza A/B/C virus, etc. It is designed for detection, identification, and mutation analysis of 36 respiratory disease-related viruses. The purified RNA sample can be directly used for library preparation and hybrid capture by a simple and high-throughput workflow.

As the virus mutates, the panel contains sufficient targeted regions. With sequencing, these mutations can also be tracked to study the path of infection and examine different strains.

After the launch of those products, CD Genomics has received sequencing data and samples from several customers who tested those panels and the results showed that they are reliable and efficient.

About CD Genomics

CD Genomics was established in 2004, aiming at providing the research community with high quality Next Generation Sequencing, PacBio SMRT sequencing, and microarray services. Due to the demand for our services has been increased; CD Genomics has already updated its technology platform to mainstream NGS and microarray instruments.